Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Garry A. Neil will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 4:00 PM ET in New York. A live webcast will be available on the Company's website, and a replay will last for 90 days. Avalo Therapeutics focuses on precision medicine, aiming to develop targeted therapeutics for immunology and rare genetic diseases. Their clinical candidates are backed by proven mechanisms and established proof-of-concept to enhance success probability.
Avalo Therapeutics announced the dosing of the first patient in its Phase 2 PEAK trial, investigating AVTX-002 for non-eosinophilic asthma treatment. This randomized, double-blind, placebo-controlled study involves around 80 participants and focuses on the safety and efficacy of AVTX-002 over 12 weeks. The primary endpoint evaluates asthma-related events in patients. With nearly half of asthma patients affected by non-eosinophilic asthma, this trial could address a significant unmet medical need in asthma treatment.
Avalo Therapeutics (Nasdaq: AVTX) will have its CEO, Garry A. Neil, present virtually at the H.C. Wainwright Global Life Sciences Conference from May 23-26, 2022. The pre-recorded presentation will be available on May 24, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website under the 'News/Events' section. Avalo is focused on developing targeted therapeutics for significant unmet clinical needs, particularly in immunology and rare genetic diseases, with a diverse portfolio aimed at delivering meaningful medical impact.
Avalo Therapeutics (AVTX) announced significant updates including the initiation of Phase 2 clinical trials for AVTX-002 in non-eosinophilic asthma and AVTX-803 for leukocyte adhesion deficiency type II. The company executed a workforce reduction of approximately one third to align with pipeline prioritization, aiming to reduce expenses over time. As of March 31, 2022, Avalo reported cash and cash equivalents of $38 million, a decrease driven primarily by operating expenses. The net loss for Q1 2022 was $22.1 million, reflecting continued investment in pipeline development.
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage precision medicine company, announced participation at Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022, at 1:20 p.m. ET. The event will showcase Avalo's innovative therapies, focusing on unmet clinical needs in immunology and rare genetic diseases. A live webcast will be available on their website. Avalo emphasizes its commitment to developing targeted therapeutics, and the potential impact of its portfolio aimed at enhancing patient care.
Avalo Therapeutics (AVTX) announced key updates, including the promotion of Dr. Garry Neil to CEO and Chris Sullivan to CFO. The company plans to initiate a Phase 2 trial for AVTX-002 targeting moderate to severe Non-eosinophilic Asthma, with topline data expected in Q4 2022. As of December 31, 2021, Avalo reported cash and equivalents of $54.6 million, a $35.7 million increase from 2020, driven by public offerings and debt facilities. However, total operating expenses rose by $8 million, primarily due to R&D costs.
Avalo Therapeutics has announced a leadership transition with Dr. Garry Neil appointed as Chief Executive Officer, effective February 14, 2022. Chris Sullivan has been promoted to Chief Financial Officer. The previous CEO and CFO, Mike Cola and Schond Greenway, respectively, have stepped down. The Board expressed appreciation for their contributions while highlighting the firm's promising future, particularly with the development of AVTX-002 for inflammatory diseases. Both Neil and Sullivan bring extensive experience to their new roles, aiming to enhance operational success and shareholder value.
Avalo Therapeutics, a clinical-stage precision medicine company (Nasdaq: AVTX), announced participation at the 2022 BIO CEO and Investor Conference, taking place in New York City from February 14-15 and virtually until February 17, 2022. The senior management team will present and hold 1x1 meetings, with a pre-recorded presentation available from February 11, 2022, for registered attendees. Avalo focuses on developing targeted therapeutics for unmet clinical needs in immunology and rare genetic diseases, aiming to enhance patient outcomes through innovative therapies.
Avalo Therapeutics announced the appointment of Stephen Smolinski as Chief Commercial Officer effective January 3, 2022. He brings over 25 years of experience in commercial strategy development, having previously held senior roles at various biotechnology firms. Smolinski aims to enhance Avalo’s commercial capabilities and business development activities, particularly for the AVTX-002 therapy. As part of the hiring, he received a stock option for 400,000 shares of common stock, vesting over four years. This strategy is aligned with Avalo's focus on targeted therapeutics.
Avalo Therapeutics (AVTX) reported a positive update on its clinical programs, emphasizing the success of AVTX-002 in treating Crohn’s disease, where 50% of participants showed mucosal healing. The company plans to expand AVTX-002 for non-eosinophilic asthma, with Phase 2 trial results expected in late 2022. Additionally, while AVTX-007 was safe in multiple myeloma trials, it showed no efficacy and will focus on Adult Onset Still’s Disease moving forward. Avalo's rare disease programs are also progressing, with multiple trials scheduled for 2022.